{
  "pmcid": "4877187",
  "sha256": "ecff99b24c554acc3aad39de723db6ef6e5b9e109ca9b5b823d3991bd4c761b4",
  "timestamp_utc": "2025-11-09T16:01:06.615029+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 8.967358408992652,
    "reading_ease": 47.72467646634965,
    "word_count": 257
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A parallel-group, multicenter, double blind, randomized, controlled clinical trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "adults after gastrointestinal, vascular, or cardiac surgery who required PN and SICU care. Subjects were without significant renal or hepatic failure or shock at entry."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Controls (n = 75) received standard GLN-free PN (STD-PN); the GLN group (n = 75) received PN containing alanyl-GLN dipeptide (0.5 g/kg/d)"
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective: To determine whether glutamine (GLN)-supplemented parenteral nutrition (PN) improves clinical outcomes in surgical ICU (SICU) patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Hospital mortality and infections were primary endpoints."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized"
      },
      "Blinding": {
        "score": 2,
        "evidence": "double blind"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Controls (n = 75); the GLN group (n = 75)"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "There were 11 hospital deaths (14.7%) in the GLN-PN group and 13 deaths in the STD-PN group and (17.3%; difference, −2.6%; 95% confidence interval −14.6 to 9.3%; P = 0.66)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Other clinical outcomes and adverse events were similar."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}